The Potential Role of Combination Adjuvant Immunotherapy in NSCLC

Opinion
Video

A group of experts in oncology investigates the feasibility of combination adjuvant immunotherapy in NSCLC consolidation, assessing the utilization of multiple immune checkpoint inhibitors and scrutinizing the rationale, with a focus on findings from the COAST study and PACIFIC-8 studies.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content
The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line non-squamous NSCLC.

Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC

Roman Fabbricatore
November 30th 2025
Article

The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line nonsquamous NSCLC.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Blood-Based Screening Test May Increase Preclinical Lung Cancer Detection

Roman Fabbricatore
November 22nd 2025
Article

The blood-based test detected 31% of lung cancers one year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

Tarlatamab Earns Traditional FDA Approval in ES-SCLC

Russ Conroy
November 19th 2025
Article

Data from the DeLLphi-304 trial support the full approval of tarlatamab in this extensive-stage small cell lung cancer population.

Results from the SOHO-01 trial led to the approval of sevabertinib for patients with non-squamous NSCLC.

FDA Approves Sevabertinib in Non-Squamous NSCLC

Tim Cortese
November 19th 2025
Article

Results from the SOHO-01 trial led to the approval of sevabertinib for patients with non-squamous NSCLC.